13 maggio 2025 – Granite Bio AG, a clinical-stage immunology company developing first-in-class antibodies that target the root causes of a variety of inflammatory, autoimmune and fibrotic conditions, has emerged from stealth with USD 100 million in funding. This includes a USD 30 million Series A led by founding investors Versant Ventures and Novartis Venture Fund, and a USD 70 million Series B led by Forbion and Sanofi Ventures.

Granite Bio is pioneering a new approach to tackling inflammation, autoimmunity, and fibrosis by addressing fundamental disease drivers at their source. With the support of the investors, Granite Bio is advancing a pipeline of first-in-class therapies with the potential to transform patient outcomes. Both of Granite Bio’s lead molecules were developed in collaboration with Versant’s Ridgeline Discovery Engine in Basel, Switzerland, and originated from the laboratories of Professor and Scientific Co-Founder Matthias Mack at University of Regensburg.

Walder Wyss advised founding investors Versant Ventures and Novartis Venture Fund on all legal aspects relating the inception of Granite Bio as well as relating to the Series A and Series B financing rounds. The Walder Wyss team included Robert von Rosen (Partner, Corporate/M&A and Venture Capital), Alexander Gutmans (Partner, Corporate/M&A and Venture Capital) as well as Karina Tschon (Managing Associate, Corporate/M&A and Venture Capital) and Lucas Maurer (Senior Associate, Corporate/M&A).